FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037322433> ?p ?o ?g. }

• W3037322433 endingPage "2883" @default.
• W3037322433 startingPage "2871" @default.
• W3037322433 abstract "The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease (P = .01), and elevated lactate dehydrogenase (LDH; P ≤ .01). The 1-year progression-free (PFS) and overall survival (OS) rates were 40% and 65% in non-BT patients vs 21% and 48% in BT patients (P = .01 and .05, respectively). Twenty-four patients (16%) did not receive axi-cel, most commonly because of lymphoma progression (88%), despite 80% (n = 19) receiving BT. Among 124 patients who received axi-cel, 50% (n = 62) received BT with ST (n = 45), RT (n = 11), or CMT (n = 6); 1-year PFS and OS rates were not significantly different between BT and non-BT cohorts (P = .06 and .21, respectively). There was no difference in proportion of patients with IPI ≥3, limited-stage disease, or elevated LDH between ST, RT, and CMT groups. Compared with non-BT patients, 1-year PFS was inferior for ST-bridged patients (P = .01). RT-bridged patients had improved PFS compared with ST-bridged patients (P = .05). Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy. Future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes." @default.
• W3037322433 created "2020-07-02" @default.
• W3037322433 creator A5007688820 @default.
• W3037322433 creator A5009933533 @default.
• W3037322433 creator A5010407419 @default.
• W3037322433 creator A5016734314 @default.
• W3037322433 creator A5021262821 @default.
• W3037322433 creator A5021496101 @default.
• W3037322433 creator A5024844183 @default.
• W3037322433 creator A5028677309 @default.
• W3037322433 creator A5030802556 @default.
• W3037322433 creator A5031498320 @default.
• W3037322433 creator A5035666092 @default.
• W3037322433 creator A5037878906 @default.
• W3037322433 creator A5038196228 @default.
• W3037322433 creator A5039574726 @default.
• W3037322433 creator A5045724173 @default.
• W3037322433 creator A5064752432 @default.
• W3037322433 creator A5069043926 @default.
• W3037322433 creator A5074654320 @default.
• W3037322433 creator A5082892912 @default.
• W3037322433 date "2020-06-26" @default.
• W3037322433 modified "2023-10-14" @default.
• W3037322433 title "Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma" @default.
• W3037322433 cites W2023809901 @default.
• W3037322433 cites W2039217762 @default.
• W3037322433 cites W2119147717 @default.
• W3037322433 cites W2598700764 @default.
• W3037322433 cites W2754562068 @default.
• W3037322433 cites W2773804840 @default.
• W3037322433 cites W2775369717 @default.
• W3037322433 cites W2787621143 @default.
• W3037322433 cites W2889673537 @default.
• W3037322433 cites W2903062212 @default.
• W3037322433 cites W2903225254 @default.
• W3037322433 cites W2905654445 @default.
• W3037322433 cites W2946366893 @default.
• W3037322433 cites W2954869918 @default.
• W3037322433 cites W2956358944 @default.
• W3037322433 cites W2963496214 @default.
• W3037322433 cites W2980400657 @default.
• W3037322433 cites W2985461348 @default.
• W3037322433 cites W2990607410 @default.
• W3037322433 cites W3024978145 @default.
• W3037322433 cites W3026897105 @default.
• W3037322433 cites W4205736005 @default.
• W3037322433 cites W4293241248 @default.
• W3037322433 doi "https://doi.org/10.1182/bloodadvances.2020001837" @default.
• W3037322433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7362355" @default.
• W3037322433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32589728" @default.
• W3037322433 hasPublicationYear "2020" @default.
• W3037322433 type Work @default.
• W3037322433 sameAs 3037322433 @default.
• W3037322433 citedByCount "111" @default.
• W3037322433 countsByYear W30373224332020 @default.
• W3037322433 countsByYear W30373224332021 @default.
• W3037322433 countsByYear W30373224332022 @default.
• W3037322433 countsByYear W30373224332023 @default.
• W3037322433 crossrefType "journal-article" @default.
• W3037322433 hasAuthorship W3037322433A5007688820 @default.
• W3037322433 hasAuthorship W3037322433A5009933533 @default.
• W3037322433 hasAuthorship W3037322433A5010407419 @default.
• W3037322433 hasAuthorship W3037322433A5016734314 @default.
• W3037322433 hasAuthorship W3037322433A5021262821 @default.
• W3037322433 hasAuthorship W3037322433A5021496101 @default.
• W3037322433 hasAuthorship W3037322433A5024844183 @default.
• W3037322433 hasAuthorship W3037322433A5028677309 @default.
• W3037322433 hasAuthorship W3037322433A5030802556 @default.
• W3037322433 hasAuthorship W3037322433A5031498320 @default.
• W3037322433 hasAuthorship W3037322433A5035666092 @default.
• W3037322433 hasAuthorship W3037322433A5037878906 @default.
• W3037322433 hasAuthorship W3037322433A5038196228 @default.
• W3037322433 hasAuthorship W3037322433A5039574726 @default.
• W3037322433 hasAuthorship W3037322433A5045724173 @default.
• W3037322433 hasAuthorship W3037322433A5064752432 @default.
• W3037322433 hasAuthorship W3037322433A5069043926 @default.
• W3037322433 hasAuthorship W3037322433A5074654320 @default.
• W3037322433 hasAuthorship W3037322433A5082892912 @default.
• W3037322433 hasBestOaLocation W30373224331 @default.
• W3037322433 hasConcept C10205521 @default.
• W3037322433 hasConcept C121332964 @default.
• W3037322433 hasConcept C126322002 @default.
• W3037322433 hasConcept C141071460 @default.
• W3037322433 hasConcept C142424586 @default.
• W3037322433 hasConcept C143998085 @default.
• W3037322433 hasConcept C2777371436 @default.
• W3037322433 hasConcept C2779338263 @default.
• W3037322433 hasConcept C28328180 @default.
• W3037322433 hasConcept C54355233 @default.
• W3037322433 hasConcept C71924100 @default.
• W3037322433 hasConcept C86803240 @default.
• W3037322433 hasConcept C87355193 @default.
• W3037322433 hasConcept C90924648 @default.
• W3037322433 hasConceptScore W3037322433C10205521 @default.
• W3037322433 hasConceptScore W3037322433C121332964 @default.
• W3037322433 hasConceptScore W3037322433C126322002 @default.
• W3037322433 hasConceptScore W3037322433C141071460 @default.
• W3037322433 hasConceptScore W3037322433C142424586 @default.

• next